Ultragenyx Pharmaceutical Inc. (RARE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RARE currently has 96.3M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 16.65% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2025 |
10-Q filing | 96.3M shares outstanding |
96M | 0 |
| Feb 19, 2025 |
10-K filing | 90.5M shares outstanding |
91M | 0 |
| Nov 06, 2024 |
10-Q filing | 95.5M shares outstanding |
95M | 0 |
| Aug 02, 2024 |
10-Q filing | 86.6M shares outstanding |
87M | 0 |
| May 03, 2024 |
10-Q filing | 84.3M shares outstanding |
84M | 0 |
| Feb 21, 2024 |
10-K filing | 82.3M shares outstanding |
82M | 0 |
| Nov 03, 2023 |
10-Q filing | 82.1M shares outstanding |
82M | 0 |
| Aug 04, 2023 |
10-Q filing | 70.9M shares outstanding |
71M | 0 |
| May 05, 2023 |
10-Q filing | 70.4M shares outstanding |
70M | 0 |
| Feb 17, 2023 |
10-K filing | 69.9M shares outstanding |
70M | 0 |
| Nov 03, 2022 |
10-Q filing | 70.1M shares outstanding |
70M | 0 |
| Jul 29, 2022 |
10-Q filing | 70.0M shares outstanding |
70M | 0 |
| May 06, 2022 |
10-Q filing | 69.9M shares outstanding |
70M | 0 |
| Feb 15, 2022 |
10-K filing | 69.4M shares outstanding |
69M | 0 |
| Nov 03, 2021 |
10-Q filing | 68.2M shares outstanding |
68M | 0 |
| Aug 03, 2021 |
10-Q filing | 67.6M shares outstanding |
68M | 0 |
| May 05, 2021 |
10-Q filing | 67.5M shares outstanding |
67M | 0 |
| Feb 12, 2021 |
10-K filing | 66.9M shares outstanding |
67M | 0 |
| Oct 27, 2020 |
10-Q filing | 61.0M shares outstanding |
61M | 0 |
| Oct 23, 2020 |
8-K filing: Ultragenyx Pharmaceutical Inc. purchased 7,825,797 shares of Solid Biosciences Inc.'s common stock for $40 million as part of a strategic collaboration. ($40.0M proceeds) |
61M | 0 |
| Jul 30, 2020 |
10-Q filing | 61.1M shares outstanding |
61M | 0 |
| May 07, 2020 |
10-Q filing | 59.7M shares outstanding |
60M | 0 |
| Apr 01, 2020 |
8-K filing: Ultragenyx Pharmaceutical Inc. sold 1,243,913 shares of common stock to Daiichi Sankyo Company, Limited for $75 million. ($75.0M proceeds) |
58M | 0 |
| Feb 14, 2020 |
10-K filing | 57.9M shares outstanding |
58M | 0 |